Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you use immunotherapy in patients with HIV and a positive viral load?
Related Questions
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
In patients with stage III NSCLC who experience locoregional recurrence after neoadjuvant chemoimmunotherapy, surgery, and maintenance immunotherapy, and are treated with definitive chemoradiation at recurrence—what is the optimal systemic therapy strategy post-chemoradiation?
Would you offer tarlatamab to patients with metastatic EGFR+ NSCLC that transformed into SCLC?
Is there any data on the safety or efficacy of combining osimertinib-based therapy with HER2-targeted treatment in patients with EGFR-mutant NSCLC and concurrent HER2-positive breast cancer?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
Would you continue tarlatamab in CNS-only progression of small cell cancer if there is no systemic disease?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
What would your approach be to treatment in a patient with stage IV thymic squamous cell carcinoma who received neoadjuvant carboplatin, paclitaxel, and ramucirumab and underwent R1 resection?
